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Diagnosis
Pulmonary arterial hypertension (PAH) is rare and, if untreated, has a median sur-
vival of 2–3 years. Pulmonary arterial hypertension may be idiopathic (IPAH) but is
frequently associated with other conditions. Despite increased awareness, therapeu-
tic advances, and improved outcomes, the time from symptom onset to diagnosis
remains unchanged. The commonest symptoms of PAH (breathlessness and fatigue)
are non-speciﬁc and clinical signs are usually subtle, frequently preventing early di-
agnosis where therapies may be more effective. The failure to improve the time to
diagnosis largely reﬂects an inability to identify patients at increased risk of PAH
using current approaches. To date, strategies to improve the time to diagnosis have
focused on screening patients with a high prevalence [systemic sclerosis (10%),
patients with portal hypertension assessed for liver transplantation (2–6%), carriers
of mutations of the gene encoding bone morphogenetic protein receptor type II, and
ﬁrst-degree relatives of patients with heritable PAH]. In systemic sclerosis, screening
algorithms have demonstrated that patients can be identiﬁed earlier, however,
current approaches are resource intensive. Until, recently, it has not been consid-
ered possible to screen populations for rare conditions such as IPAH (prevalence
5–15/million/year). However, there is interest in the use of artiﬁcial intelligence
approaches in medicine and the application of diagnostic algorithms to large health-
care data sets, to identify patients at risk of rare conditions. In this article, we re-
view current approaches and challenges in screening for PAH and explore novel
population-based approaches to improve detection.
Introduction
Pulmonary arterial hypertension (PAH) is a rare, cardiopul-
monary disease with insidious onset and usually rapid dis-
ease progression.1,2 Common symptoms of PAH, such as
breathlessness and fatigue, are non-specific and patients
frequently delay seeking medical advice.3 Although disease
awareness amongst healthcare professionals has improved,
patients frequently experience significant delays between
initial symptom onset and a confirmed PAH diagnosis.3 The
time to diagnosis can be compounded in elderly patients by
the presence of comorbidities.4–6 Consequently, many
patients have advanced disease at diagnosis7 with 1-year
mortality rates of up to 15% for patients with idiopathic, fa-
milial, or toxin- or drug-induced PAH8–12 and up to 30% for
systemic sclerosis-associated PAH (PAH-SSc).13
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Reducing the time to diagnosis is important. It may
lessen the emotional impact of uncertainty in patients, the
number of investigations performed and allow treatment
at an earlier stage where therapies may be more effec-
tive.8,12–17 This may be achieved by systematic screening
of at-risk populations.14,18 There are a number of tools in-
cluding, clinical assessment, blood biomarkers, imaging,
and exercise testing that can be utilized in screening
programmes to improve the detection of PAH.1,19–23
In this article, we review the rationale for screening for
PAH, currently available tools and approaches, and explore
the challenges of improving the detection of PAH using
novel methods.
Screening strategies for pulmonary arterial
hypertension
Reasons to screen for pulmonary arterial
hypertension
Over the last two decades, there have been significant
advances in the treatment of PAH and a more than doubling
of survival24,25 but the time from symptom onset to diagno-
sis remains unchanged at around 2 years.26 A recurring
theme of studies is the frequent interaction with health-
care services prior to diagnosis and missed opportunities
for earlier diagnosis, particularly in patients with idio-
pathic PAH (IPAH).27 Initial PAH symptoms are non-specific
and include breathlessness on exertion, fatigue, chest
tightness similar to angina, palpitations, dizziness, and an-
kle swelling in advanced disease.1 Patients presenting with
these symptoms are often investigated for other cardiac,
pulmonary, neurological, musculoskeletal, haematologi-
cal, or age-related causes during multiple consultations
with primary care and specialist physicians before PAH is
diagnosed particularly in its idiopathic form (Figure 1).1,28
In patients with systemic sclerosis (SSc), an early-
detection screening programme for the identification of
patients at greatest risk of developing PAH was compared
with routine clinical practice.14 The results showed that all
16 patients (100%) in the early detection cohort were alive
at 1 year compared with 12 out of the 16 (75%) who were
diagnosed using routine clinical practice. The importance
of early detection became more relevant over time with
survival rates at 3, 5, and 8 years of 81%, 73%, and 64%, re-
spectively, in the screening cohort compared with 31%,
25%, and 17%, respectively, in the non-screened cohort.14
Despite the small patient numbers and limitations such as
lead time and length-time bias, these results provide a
rationale for screening at-risk patient populations and
diagnosing PAH at a stage when it may be more amenable
to treatment.
Definition and principles for screening in
pulmonary arterial hypertension
Screening can be defined as the systematic use of a test, or
tests, in at-risk individuals to identify disease before
symptom onset.30 However, in practice, it is frequently
extended to include mildly symptomatic patients or those
with early disease. Years can elapse between symptom on-
set and diagnosis in PAH, so there is value in considering
adoption of screening approaches to improve the detection
of PAH in symptomatic patients, where PAH is rarely
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Figure 1 Schematic representation of a typical patient journey prior to pulmonary arterial hypertension diagnosis. Patients frequently delay seeking
medical advice following the onset of symptoms and have multiple interactions with primary care and specialist physicians once they do.27–29 Typical
investigations and their timing are shown and the potential for deployment of interventions to improve detection are indicated by light blue arrows.
COPD, chronic obstructive pulmonary disorder; CT, computed tomography; DLco, pulmonary diffusing capacity for carbon monoxide; ECG, electrocardio-
gram; PAH, pulmonary arterial hypertension; PCP, primary care physician; PH, pulmonary hypertension; RHC, right heart catheterization.
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considered in the initial differential diagnosis. Ideally, a
screening test should have high sensitivity and specificity,
be reproducible, non-invasive, inexpensive, easily accessi-
ble and able to be performed in settings where results can
be acted uponwith further confirmative testing, or specific
treatment.
Several important questions need to be considered in
the conceptualization of a screening programme in order
tomaximize the benefit–risk ratio for each patient (Box 1).
Whom to screen: relevant at-risk populations
Screening is not feasible in all asymptomatic at-risk
patients, so it is essential that the appropriate target popu-
lations are selected. Evidence-based recommendations for
screening and diagnosis of PAH are currently only available
for PAH associated with connective tissue diseases (CTDs)31
and state that patients with SSc, mixed CTD or other CTDs
with scleroderma features should be screened for PAH.
However, the prevalence of PAH in patients with CTDs other
than SSc may be too low to justify wholescale screening of
asymptomatic patients, using current approaches. In sys-
temic lupus erythematosus, where the prevalence of PAH is
thought to be 1% and therefore considerably lower
than SSc, the potential benefits of screening are currently
being investigated.32 Other patient groups with a high
prevalence of PAH include individuals with congenital heart
disease, portal hypertension, HIV infection, or a genetic
pre-disposition to PAH.33
Heterozygous mutations of the gene encoding bone mor-
phogenetic protein receptor type II (BMPR2) account for
80% of familial PAH/heritable PAH (FPAH/HPAH) cases and
between 10% and 20% of sporadic cases1,34,35; patients with
BMPR2 mutations are younger and have more severe dis-
ease at diagnosis and are at an increased risk of death or
lung transplantation compared with those without BMPR2
mutations.36 Therefore, genetic screening is potentially of
considerable benefit, although the emotional impact on
patients and family members found to have PAH-associated
mutations needs to be considered. The imminent results of
the DELPHI-2 study (NCT01600898) evaluating multimodal
PAH screening in asymptomatic BMPR2 mutation carriers,
are eagerly awaited. Future family studies in patients with
confirmed FPAH/HPAH such as the UK National Cohort
Study of Idiopathic and Heritable Pulmonary Arterial
Hypertension (NCT01907295) could help establish the risk
of developing PAH based on genotype.37 However, such
studies are restricted by relatively small patient numbers
and the time required to accumulate data. One genotype–
phenotype correlation study has revealed a non-BMPR2 ge-
netic trait associated with a pulmonary hypertensive
response to exercise and hypoxia in relatives of patients
with IPAH or FPAH/HPAH.22 Further studies are required
to ascertain the viability of identification of this and other
genetic traits to predict the development of PAH.
The low percentage of asymptomatic patients with
portal hypertension (between 2% and 6%) or HIV (0.5%)
who develop PAH, means wide-scale screening is currently
not cost-effective.38,39 However, because of the risks
associated with surgery in PAH, it is logical to offer PAH
screening in patients with portal hypertension referred
for liver transplantation. Few epidemiological studies have
been carried out in patients with CTD other than SSc. In
congenital heart disease, the prevalence of PAH is high,
particularly in unrepaired post-tricuspid lesions (ventricu-
lar septal defect and patent ductus arteriosus).40 No spe-
cific evidence-based guidelines currently exist for
screening for PAH in congenital heart disease although
these patients should be managed in specialist centres and
at-risk patients evaluated.
Pulmonary arterial hypertension diagnostic tools
currently used to screen for pulmonary arterial
hypertension
The joint European Society of Cardiology/European
Respiratory Society guidelines have identified several key
diagnostic tests that could be used for screening.1
Echocardiography
Doppler transthoracic echocardiography (TTE) is recom-
mended whenever PAH is suspected and has the highest
level of evidence of current tests used to screen for PAH.1 A
recent study including 313 492 patients undergoing echo-
cardiography demonstrated that TTE is widely used and has
the potential to identify patients at a population level.
Importantly, even mild elevations of systolic pulmonary ar-
tery pressure (PAP) were associatedwith a poor outcome.41
The tricuspid regurgitation velocity (TRV) is an important
TTE parameter, allowing an estimate of the systolic PAP.
Although higher TRV values are associated with an in-
creased probability of PAH, systolic PAP estimations in an
individual patient may be inaccurate.42
Other echocardiographic parameters associated with
PAH include, but are not limited to, measurements from
the ventricles (e.g. flattening of the interventricular sep-
tum), the pulmonary artery (e.g. reduced right-ventricular
outflow tract acceleration time), or increases in inferior
vena cava diameter or right atrium area.1,43 Evidence
from the DETECT study,18 which included a wide range of
echocardiographic variables in its screening model, has
Box 1 Points for consideration in the development
of a PAH screening programme
Which patients are considered to be most at risk of
developing PAH?
Is the patient population to be screened completely
asymptomatic?
Will early detection and/or treatment result in tangible
clinical improvements in outcomes?
Is the screening associated with any risks?
How frequently should screening be performed?
What is the potential for false positive results
(specificity vs. sensitivity)?
How cost-effective is the screening?
Will the screening, particularly those identifying
putative genetic markers, have any emotional impact
on the patient?
Screening strategies for PAH K11
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suggested that TRV and right atrial area are the key
echocardiographic parameters that should be assessed in
selection of SSc patients for right heart catheterization
(RHC) referral. Despite limitations such as challenges in im-
age acquisition particularly in chronic lung disease, it is
widely available and frequently used in the assessment of
unexplained breathlessness.
Pulmonary function tests
The majority of patients with PAH have decreased lung
diffusion capacity for carbon monoxide (DLCO).
1 Significant
reductions in DLCO are frequently seen in asymptomatic
patients subsequently diagnosed with PAH-SSc and is consid-
ered a robust predictor of the disease.44,45 In particular, a
DLCO of<60% can be used to enrich for a population at higher
risk of PAH.18 Approximately 75% of patients with IPAH, par-
ticularly older patients or those with an increased tobacco
exposure, have a reduced DLCO.
46,47 However, a normal DLCO
does not exclude a diagnosis, particularly in patients with
FPAH/HPAH where DLCO can be preserved.
1 A recent study
evaluating cardiopulmonary abnormalities in newly diag-
nosed patients with pulmonary hypertension demonstrated
that abnormalities of DLCO correlated with World Health
Organization (WHO) functional class (FC) although reduc-
tions in exercise capacity were more sensitive than DLCO for
the detection of pulmonary hypertension in asymptomatic
patients in WHO FC I.48 A parameter calculated from pulmo-
nary function tests (PFTs) is the forced vital capacity/DLCO
ratio (both expressed as percentage of the predicted values).
In SSc, a ratio 1.8 suggests more pronounced reduction
of gas transfer when compared with lung volume, and by
inference higher likelihood of pulmonary vascular disease.
This parameter is part of the algorithm derived from the
Australian Scleroderma Cohort Study (ASCS).49
Cardiopulmonary exercise testing
Cardiopulmonary exercise testing (CPET) allows discrimi-
nation between the metabolic, cardiovascular, and pulmo-
nary components of exercise intolerance.50 However, it
requires expertise and specialist facilities, currently limit-
ing its use, and as such it is not currently recommended as
a screening tool for PAH.1,2,51,52 The typical CPET findings
in patients with PAH include reductions in peak rate of oxy-
gen consumption (VO2), ratio of oxygen consumption to
heart rate (O2 pulse), work rate, anaerobic threshold, and
an increase in the ratio of minute ventilation to CO2 pro-
duction (VE/VCO2 slope) and the ratio of dead space to tidal
volume (VD/VT).
53–55 Dumitrescu et al.56 recently investi-
gated the utility of CPET in early detection of PAH in 173
SSc patients, who also underwent RHC, and found peak VO2
to be the most accurate parameter for diagnosis with val-
ues above 18.7mL/kg/min excluding PAH in all patients
(i.e. a negative predictive value of 1.0; 100% of patients
with values exceeding this threshold did not have PAH). In
addition, a nadir VE/VCO2 ratio of>45.5 had a positive pre-
dictive value of 1.0.56 A cross-sectional study of patients
with echocardiographic findings suggestive of PH also dem-
onstrated the value of measuring peak VO2 and VE/VCO2
slope to aid early detection of PAH.57 The PH patients (18
PAH and 9 CTEPH) had lower peak VO2, compared with non-
PH patients (n¼ 61; 877 vs. 1254 mL/min, respectively)
and multivariable logistic regression analyses identified
VE/VCO2 slope and anaerobic threshold as independent
predictors of PH.57 Further investigation into the role of
CPET in early detection of PAH and standardization of the
technique is required to support its recommendation in
clinical practice.
Blood biomarkers
Biomarker studies to screen for PAH are at an early stage of
development and the majority of studies highlighting a po-
tential role for blood biomarkers have been conducted in
enriched populations of patients with suspected or con-
firmed PAH diagnoses.20,58–60Of the current proposed blood
biomarkers, only brain natriuretic peptide (BNP), N-termi-
nal pro-B-type natriuretic peptide (NT-pro-BNP), and se-
rum urate are included in currently used screening
alogrithms.18,49 Pulmonary hypertension causes an in-
crease in myocardial wall stress resulting in the release of
NT-pro-BNP (the inactive pre-cursor of BNP), from cardio-
myocytes.61,62 Blood concentration of this peptide has
been shown to be a useful biomarker for PAH,1,23,63 particu-
larly in PAH-SSc, although it may not identify patients with
mild disease.49 Elevated NT-pro-BNP blood levels can also
occur in patients with conditions such as left ventricular
dysfunction and advanced renal insufficiency, so care is
needed to eliminate any other potential source of the ab-
normality before further assessments are undertaken. A
small number of studies have demonstrated that serum
urate levels64,65 are elevated in patients with PAH, and re-
flect disease severity.64 Serum urate is the final product
of purine degradation and elevated levels are thought
to reflect impaired oxidative metabolism occurring as a
consequence of tissue ischaemia.66 In the DETECT study,
elevated levels were predictive of PAH.18
The diagnostic and prognostic value of blood biomarkers
in asymptomatic subjects or specific at-risk populations
needs further research but they have the potential to
play an important role in screening programmes, given the
simplicity of blood testing.
Electrocardiography
Since 1995, an electrocardiography-based mass screening
system for general paediatric heart disease has been imple-
mented in Japan. Between 2005 and 2012, the screening
detected a unique subpopulation of paediatric patients
with IPAH or HPAH associated with advanced pulmonary
haemodynamics at rest in subjects with no obvious right
heart failure.67 Although the screening failed to identify
early stage PAH it did improve disease detection. In
patients with SSc screened for PAH in the DETECTstudy, the
presence of right axis deviation aided discrimination
between patients with and without PAH and is incorporated
in the screening algorithm.18
Current screening algorithms
The development and validation of screening algorithms to
help identify patients with PAH is of considerable clinical
importance. However, validated screening algorithms for
PAH currently only exist for patients with SSc (Figure 2) and
there is limited guidance for other patient groups
(Table 1).
K12 D.G. Kiely et al.
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Since the initial French study demonstrating the ability
of a screening regimen based on echocardiography and
symptoms to identify patients with SSc with milder haemo-
dynamic disease,14 a number of PAH screening approaches
have been proposed. The DETECT algorithm is a highly
sensitive, two-step, non-invasive prediction score, which
can be used to screen for SSc-PAH in at-risk adults
(SSc >3 years; DLCO <60% predicted).
18 This DETECT study
performed RHC in all patients and could therefore assess
missed PAH diagnoses (false negatives) not provided by
previous studies. This study proposes a two-step approach
to assessing patients with SSc for PAH. In Step 1, patients
undergo a series of six tests, including clinical assessment
for the presence of telangiectasia, PFTs, electrocardio-
gram, and serum biomarkers (anticentromere antibody,
NT-pro-BNP, and uric acid) to identify those requiring fur-
ther assessment by TTE (Step 2). Those with a high-risk
score should then be referred for a RHC (Figure 2A). The
ASCS49 has also assessed a non-invasive screening algorithm
for PAH based on NT-pro-BNP levels and lung function
Confirmed PAH
Right heart catherization
Australian Scleroderma Interest Group ItinerAIR Sclérodermie algorithm
SSc patients with no severe pulmonary
function abnormalities
DETECTA
B C
SSc
patient
Individual risk points in Step 1 0 10 20 30 40 50 60 70 80 90 100
PFT and NT-proBNP Doppler echocardiography
VTR <2.5 m/s VTR 2.5–3 m/s VTR >3 m/s
Right heart catheterization
DLCOcorr≥70 % predicted
& FVC/DLCO <1.8
And
NT-proBNP≤210 pg/ml 
DLCOcorr <70 % predicted
& FVC/DLCO≥1.8 
And/Or
NT-proBNP >210 pg/ml
Echocardiography ±
HRCT, 6MWT (optional)
NO DYSPNOEA
(or dyspnoea explained
by another cause)
DYSPNOEA
(not explained
by another cause)
Suspected PAH
Suspected PAHNo PAH
Low likelihood of PAH
Repeat
screening
No PAH
FVC % predicted/DLCO % predicted
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5
Current/past telangiectasias 0 1
Serum ACA 0 1
Serum NTproBNP 0 10000
Individual risk points in Step 2 0 6010 20 30 40 50
Total risk points from Step 1 300 320 340 360 380 400 420 440
Right atrium area 0 405 10 15 20 25 30 35
TR velocity 0 51.5 2.5 3 3.5 4 4.5
3 10 30 100 300 1000 3000
Serum urate 2 102.5 3 3.5 4 4.5 5
ECG: right axis deviation 0 1
Total risk points from Step 1 220
No referral Referral to echocardiography 
440240 260 280 300 320 340 360 380 400 420
Total risk points from Step 2 10
No referral Referral to right heart catheterization
13020 30 40 50 60 70 80 90 100 110 120
Figure 2 Summary of three approaches to screen for SSc–PAH, including that of the DETECT study (A),18 that of the Australian College of Physicians
(B),49 and the ItinerAIR Scle´rodermie algorithm (C).45 ACA, anticentromere antibody; DLco, pulmonary diffusing capacity for carbon monoxide;
FVC, forced vital capacity; HRCT, high-resolution computed tomography (of lung); NTproBNP, N-terminal pro-brain natriuretic peptide; PFT, pulmonary
function test; TR, tricuspid regurgitant jet; VTR, peak velocity of tricuspid regurgitation.
Figure 2A reproduced from Annals of the Rheumatic Diseases, Coghlan et al.18 with permission from BMJ Publishing Group Ltd.
Figure 2B reproduced from Arthritis Res Ther, Thakkar et al.49 by permission from BioMed Central Ltd.: Springer Nature, under the CC-BY-2.0 license
(2013) https://creativecommons.org/licenses/by/2.0/. Permission is granted for reproduction of Figure 2C from Hachulla et al.45 Arthritis Rheum. John
Wiley and Sons. CopyrightVC 2005 by the American College of Rheumatology.
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parameters (Figure 2B). This algorithm had sensitivity, spe-
cificity, positive, and negative predictive values for the de-
tection of PAH of 94.1%, 54.5%, 61.5%, and 92.3%,
respectively. The ASCS algorithm showed significantly im-
proved diagnostic accuracy compared with the use of PFTs
or NT-pro-BNP alone and has a potential advantage of not
using TTE. It must, however, be underscored that TTE in
SSc is not exclusively performed for PAH screening but also
provides important information on left, right, valvular, and
pericardial parameters. Algorithms combining PFTs and
echocardiography to screen for PAH in SSc also exist.69 It
has been suggested that approaches combining a number
of modalities are more robust as screening tools than
approaches solely reliant on the use of a single modality.
Compared with screening approaches based on TTE alone,
DETECT identified patients with PAH-SSc with less severe
haemodynamic disease and significantly reduced the rate
of missed PAH diagnoses (4% vs. 29% based on mean PAP
25mmHg) and reduced healthcare resource usage.
DETECT was also able to identify patients with PAP
>20mmHg,18 which is relevant given the recent recom-
mendations from the World Symposium to consider this
threshold as the upper limit of normal value.33
Guidance on when and for whom to consider screening of
PAH in patients with portal hypertension or congenital
heart disease is detailed in a separate review in this supple-
ment,70 but it is also important to note that screening algo-
rithms/methods should be tailored to the at-risk
population concerned.68 Patients considered for correction
of CHD with prevalent systemic-to-pulmonary shunts
should be screened for PH by means of RHC; the presence
of PAH and the magnitude of pulmonary vascular resistance
elevation is associated with significant risk after CHD cor-
rection.71 Patients considered for liver transplantation
should be screened for PH by echocardiography followed
by RHC if needed, as the presence of PAH is associated with
significant mortality risk after transplantation.1,2 Research
is ongoing to improve PAH screening in these at risk-
populations, and this includes studies on the utility of a
new echocardiographic parameter, pulmonary arterial
stiffness, and in HIV72 and CHD populations.73 Further re-
search is needed to guide screening in at-risk populations,
particularly trials of screening algorithms for PAH as cur-
rently, there is only a body of evidence for PAH-SSc, which
we focus on here.
Unmet needs and future directions
The development and implementation of PAH screening
algorithms for patients with SSc has shown that patients
with PAH can be diagnosed with less severe haemodynamic
disease.14,18,49 However, patients with SSc represent less
than 25% of the total PAH population and there remains a
large unmet need. The improvements in diagnosing PAH in
SSc have required a large commitment and investment
from both the rheumatological and pulmonary hyperten-
sion communities. Although the DETECT study reported
that its use resulted in overall reductions in healthcare re-
source usage,18 an assessment of the ASCS algorithm74 sug-
gested that annual rescreening of patients could result in
potentially unnecessary invasive and costly RHC proce-
dures. Even though both algorithms have been shown to
be adept at early identification of PAH-SSc, full cost-
effectiveness studies of both algorithms along with greater
validation, a better understanding of optimal screening
frequency and the best use of the algorithms are required.
More research is required to identify patients with SSc who
are at low risk of developing PAH. In addition, long-term
Table 1 Risk factors for PAH and screening recommendations from guidelines
Risk factor Recommendations Screening in
asymptomatic
individuals?
Guideline society
Systemic sclerosis Echocardiogram yearly6 biomarkers/PFTs or DETECT
algorithm
Yes ACC/AHA
ESC/ERS
Annual NT-proBNP and PFTs 6 echocardiography Yes ASIG
BMPR2-mutation carriers
and ﬁrst-degree rela-
tives of patients with
familial PAH
Echocardiogram yearly Yes ACC/AHA
Systemic sclerosis Echocardiogram yearly Yes ACC/AHA
ESC/ERS
Portal hypertension Echocardiogram if liver transplantation considered Yes ACC/AHA ESC/ERS
Congenital heart disease Echocardiogram and right heart catheterization
at time of diagnosis; consider repair of defect
No ACC/AHA
HIV infection Echocardiogram only if symptomatic No ACC/AHA
ESC/ERS
Previous anorexigen use Echocardiogram only if symptomatic No ACC/AHA
ACC, American College of Cardiology; AHA, American Heart Association; ATS, American Thoracic Society; ASIG, Australian screening interest group;
ESC, European Society of Cardiology; ERS, European Respiratory Society; NT-pro-BNP, N-terminal pro-brain natriuretic peptide; PAH, pulmonary
arterial hypertension; PFT, pulmonary function test.
Reprinted by permission from Springer Nature, Nature Reviews Cardiology, Lau et al.68,VC 2014.
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outcomes of the screened populations need to show bene-
fits of early PAH detection, as previously suggested with a
screening approach based on combining TTE with a symp-
tomatic assessment.14
The success of screening algorithms in patients with SSc
is encouraging and underlines the importance of develop-
ing algorithms that are suitable for use in other patients at
risk of developing PAH. However, a large proportion of PAH
patients do not belong to an ‘at-risk’ population and the
identification of these mildly symptomatic patients
remains a challenge. Currently, timely diagnosis in these
patients relies on a systematic approach to the investiga-
tion of these patients in both the primary and secondary
care settings. The only study to investigate the impact of a
‘traditional’ screening tool on PAH detection in a general,
unselected population is a recent nationwide study of
electrocardiography-based mass screening in Japanese
schools.67 Electrocardiography-based screening for the
early detection of various cardiovascular diseases has been
mandatory in Japanese schools since 1995 but Sawada
et al. were the first to investigate the impact of this
established system on PAH detection. In this retrospective
observational study of paediatric patients with IPAH or he-
reditary PAH (HPAH) who were newly diagnosed between
2005 and 2012, 28 (41%) children were detected by
the electrocardiography-based screening. Compared with
patients in whom PAH was detected by other means
(the non-screening group), the screening group had milder
clinical symptoms (greater proportion in WHO FC I/II
and longer 6MWD) yet both groups had established PAH
(mean PAP of 60 mmHg, mean pulmonary vascular resis-
tance index of 20 Wood units*m2, mean cardiac index of
3 L/min/m2).67 This indicates that this screening pro-
gramme detected a unique subpopulation of IPAH/HPAH
patients but did not achieve ‘true’ earlier detection, since
elevated PAP is a relatively late event in PAH development.
It remains unclear whether the screening group benefited
from being diagnosed and whether this method is suitable
as a large-scale screening strategy for PAH.75 There are
also novel screeningmethods on the horizon thatmay allow
large-scale screening in a cost-effective manner. These
would have the potential to dramatically improve early de-
tection of PAH and are discussed in the next section.
Diagnostic tools that could be used to screen for
pulmonary arterial hypertension
Blood-based biomarkers
The use of blood-based biomarkers to screen for PAH is at-
tractive as blood sampling is straightforward and can be
easily deployed at a population level. The current ap-
proach to blood-based biomarkers has relied primarily on
the identification of biomarkers that reflect the impact of
the disease process on cardiac function rather than focus-
ing on biomarkers that reflect pulmonary vasculature ab-
normalities. Elevated NT-pro-BNP levels are only observed
in patients with PAH and cardiac impairment, whereas pro-
teomic, metabolomic, and microRNA approaches to bio-
marker identification may have the potential to aid earlier
diagnosis. MicroRNAs are stable and readily detected in
plasma and multiple studies have shown they are dysregu-
lated in patients with PAH76,77 with circulating levels
predicting survival in the cases of miR-15078 and miR-140-
5p79 for example. Proteomic and metabolomic analyses
have also identified a combination of nine circulating
proteins associated with a high risk of mortality, inde-
pendent of other clinical assessments80 and 62 metabo-
lites prognostic for PAH, with modified transfer RNA and
altered bioenergetics related to survival.81 The addition
of further blood-based markers to existing screening
algorithms, such as DETECT,18 and risk stratification
strategies, such as the REVEAL risk score calculator,23,82
should be explored and prospective biomarker studies
undertaken.
Volatile organic compounds
Detectable in exhaled breath, volatile organic compounds
(VOCs) have been proposed as non-invasive biomarkers for
diseases such as cancer, and more recently for PAH.83–85
Significant alterations of the exhaled VOCs among PAH
patients have been identified, both when compared
with controls or patients with other respiratory diseases,
suggesting exhaled breath analysis has a potential non-
invasive medical application in the field of PAH.84 A large
explorative study (SNOOPY2) in patients with confirmed
and suspected pulmonary hypertension (PH) has recently
been completed (NCT02782026) and results should be pre-
sented in late 2019.
Exercise testing
There are limited data on the natural history of early
pulmonary vascular disease since patients usually present
with advanced disease.7 However, it is generally accepted
that the development of exercise-induced PH precedes
resting PH. Studies using exercise echocardiography have
demonstrated that patients at risk of developing PAH,
such as relatives of patients with hereditable PAH or
IPAH, have an exaggerated rise in systolic PAP in response
to exercise.22,86 In addition, patients with exercise pul-
monary hypertension in the setting of systemic sclerosis
have an increased risk of going on to develop PAH.56
Cardiorespiratory exercise testing can also be used to iden-
tify the cause of breathlessness and increasingly is
deployed in specialized breathlessness clinics. Patients
with PAH have characteristic abnormalities reflecting a
cardiac limitation to exercise associated with increased
dead space ventilation and hyperventilation. Although
CPET provides a large amount of physiological information
it is time-consuming to perform and requires significant ex-
pertise, meaning its deployment is limited to carefully se-
lected at-risk groups. A study of 895 patients with Group 1
to Group 5 PH demonstrated that 89% of asymptomatic
(WHO FC I) patients, 93% of patients with mild breathless-
ness (WHO FC II), and 100% of patients in WHO FC III and IV
walked <80% of their predicted exercise capacity using an
incremental field walking test (incremental shuttle walking
test); this test would be more suited to screening large
populations.48
Imaging investigations
There continue to be significant advances in imaging tech-
nologies and also a lag between reporting of evidence dem-
onstrating the diagnostic value of imaging and its
Screening strategies for PAH K15
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/e
u
rh
e
a
rtjs
u
p
p
/a
rtic
le
-a
b
s
tra
c
t/2
1
/S
u
p
p
le
m
e
n
t_
K
/K
9
/5
6
7
8
7
1
1
 b
y
 U
n
iv
e
rs
ity
 o
f S
h
e
ffie
ld
 u
s
e
r o
n
 2
9
 J
a
n
u
a
ry
 2
0
2
0
implementation in clinical practice.87 Consequently, there
is a significant potential diagnostic dividend that may be
realized to aid earlier diagnosis of PAH. Many features of
pulmonary hypertension visible on a computed tomography
(CT) scan performed for the assessment of unexplained
breathlessness are frequently not reported by radiologists
or recognized by physicians. Pulmonary artery enlarge-
ment, elevated pulmonary artery to aortic ratio, right
ventricular dilation, elevated right ventricular to left ven-
tricular ratio, and abnormalities of lung perfusion, such as
centrilobular ground glass, which are observed in PAH,88
could potentially be assessed using artificial intelligence
(AI) approaches. Machine learning (ML) approaches have
been shown to improve automation and quantification of
some imaging parameters, particularly in magnetic reso-
nance imaging.89 There is a lot of interest in the application
of these approaches to more scalable imaging techniques,
such as CT, where the application of tensor-based
approaches such as those used in facial recognition soft-
ware could be used to recognize patterns consistent with a
diagnosis of pulmonary hypertension.
Healthcare utilization behaviour
While there is optimism regarding the potential to identify
early pulmonary vascular disease in SSc, until recently this
was not the case for IPAH. However, a number of investiga-
tors have recently studied the patient journey and have
postulated that a patient with IPAHmay exhibit a particular
pattern of behaviour prior to diagnosis that could poten-
tially be used to diagnose IPAH earlier.27 The DELAY study
used a combination of health records and quantitative and
qualitative interviews28 and demonstrated that patient-
driven delay, multiple general practitioner and hospital vis-
its occur prior to specialist referral. A similar pattern has
also been observed in a large descriptive cross-sectional
study of 567 patients with pulmonary hypertension.29 A re-
curring theme is a significant delay between symptom onset
and seeking medical advice and there is interest in the use
of wearable technologies and ML approaches to these large
complex datasets to develop AI algorithm approaches that
can alert patients and doctors to changes in daily levels or
patterns of activity. The Sheffield Pulmonary Hypertension
IndeX project27 aims to develop a predictive algorithm
based on routinely collected healthcare utilization data to
reduce the time to IPAH diagnosis. In this study, 127 815
adults with pulmonary hypertension were identified from a
national healthcare data set; it was determined that 589 of
these patients had probable IPAH. The incidence and demo-
graphics of these probable IPAH patients were similar to the
reported literature. In a separate cohort of 864 patients
with confirmed IPAH, data could be linked with NHS
Hospital Episode Statistics in 98.6% of cases and these
patients had an average of 18 hospital contacts in the
3 years prior to diagnosis.27 Importantly, these data have a
complexity and richness that has the potential to facilitate
an earlier diagnosis by identifying a ‘fingerprint’ that may
be deployed to detect patients at risk of IPAH. Further work
to develop, validate and, if successful, deploy such
approaches is required.
Figure 3 summarizes the potential of currently available
non-invasive tools to identify patients at risk of PAH at
different levels of disease severity.
New approaches to screening and detecting
pulmonary arterial hypertension
How best to apply existing and new screening and
diagnostic tools remains a major challenge in PAH, where
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approaches to screening and improved detection are
required for both asymptomatic patients (e.g. systemic
sclerosis) and symptomatic patients for whom a PAH
diagnosis is rarely considered as an initial diagnosis
(Figure 4).
Breathlessness clinics
As the majority of patients with PAH present with breath-
lessness, the development of specialist clinics, where
diagnostic investigations are performed by experienced
clinicians in a systematic and timely manner, could reduce
the time-to-diagnosis and also potentially allow evaluation
of aforementioned screening tools.
Application of algorithms to routinely collected large
data sets to identify patients for further evaluation
The use of AI approaches to routinely collected data is an
area of increasing interest. In many countries around the
world, large and complex data sets on healthcare resource
utilization exist. If predictive algorithms could be developed
to identify patients at increased risk of PAH, the potential
benefits could include opportunities to assess economic im-
pact of diagnostic testing and treatment, without the poten-
tial lead-time bias that exists using current approaches. In
addition, data from patients at an earlier stage of disease
may yield new insights into early molecular mechanisms and
highlight novel targets for drug development.
Conclusions
Despite evidence of the success of screening algorithms
to facilitate earlier diagnosis of PAH in SSc, progress in
diagnosing PAH earlier in other forms of PAH such as IPAH
remains disappointing. The creation of screening algorithms
for patients at risk of SSc-PAH has increased the speed and
specificity of diagnosis, potentially improving survival al-
though the costs from screening remain significant. The de-
velopment and validation of screening algorithms for PAH of
other aetiologies is required if we are to realize similar
improvements for a wider patient population. Screening for
PAH in asymptomatic at-risk patients and the development
of screening-based approaches in symptomatic patients
where the diagnosis is rarely considered are required to im-
prove detection rates and reduce the time to diagnosis. A
number of novel screening tools and approaches provide
hope to patients and physicians that the advances seen in
treatment will also be seen in the diagnostic journey.
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